Riboxin® [Inosine]

Pharmacological properties

A metabolic type of action used to treat heart disease. Inosine has antihypoxic, antiarrhythmic properties and exhibits anabolic effects, being the precursor of atf. it has a positive effect on the metabolism in the myocardium, in particular, it increases the activity of a number of enzymes that ensure cell respiration. increases the strength of heart contractions and contributes to a more complete relaxation of the myocardium in diastole due to the ability to bind calcium ions that penetrate the cells during their excitation. as a result, the stroke volume of the heart increases, and the blood supply to tissues, including the myocardium, improves. inosine also reduces platelet aggregation, stimulates the regeneration of tissues (especially the myocardium and the mucous membrane of the digestive tract).

Indications

Inosine-bhfz is used in the complex treatment of coronary heart disease (myocardial infarction, angina pectoris, heart rhythm disturbance); in case of digitalis poisoning, for the treatment of cardiomyopathies of various origins, myocarditis, myocardial dystrophy (due to physical overload, with infectious and endocrine diseases), liver diseases (hepatitis, cirrhosis, fatty degeneration), peptic ulcer of the stomach and duodenum, for urophoria, leukopenia when irradiated. as a means of improving visual function, it is used for open-angle glaucoma with normalized (using antihypertensive drugs) intraocular pressure.

Application

Inside before meals. the daily dose is set individually and is 0.6–2.4 g per day. usually, at the beginning of treatment, the drug is prescribed in a daily dose of 0.6-0.8 g (1 tablet 3-4 times a day). with good tolerability of the drug, the dose is gradually (over 2–3 days) increased first to 1.2 g per day (2 tablets 3 times a day), then to 2.4 g per day (4 tablets 3 times a day day). the duration of treatment is from 4 weeks to 1.5-3 months. with uroporphyria, inosine-bhfz is prescribed at 0.8 g per day (1 tablet 4 times a day). the duration of the course of treatment is 1-3 months.

Contraindications

Increased individual sensitivity to the components of the drug, gout.

Side effects

In patients with hypersensitivity to the drug, itching, redness of the skin may occur. occasionally - tachycardia, an increase in the level of urea in the blood, with prolonged treatment - exacerbation of gout.

special instructions

In renal failure, the use of the drug is possible only if the expected positive effect prevails over the possible risk of its use. there is no evidence of the negative effect of inosine-bhfz on drivers and other people working with potentially dangerous equipment.

Interactions

With other drugs that can lead to a decrease in the effectiveness and safety of the use of drugs, up to this time have not been identified.

With the simultaneous administration of Inosine-BCPP with β-adrenergic blockers, the effect of the drug does not decrease. When combined with cardiac glycosides, the drug can prevent the occurrence of arrhythmias.

Overdose

Perhaps an increase in the described side effects.

Storage conditions

In a dry, dark place at temperatures up to 25 ° C. expiration date - 3 years.